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Abstract
Background The ascertainment of sudden cardiac death
(SCD) in electronic health databases is challenging.
Objectives Our objective was to evaluate the applicability of
the validated computer definitionofSCDdevelopedbyChung
et al. in a retrospective study of SCD and domperidone
exposure in the Clinical Practice Research Datalink (CPRD).
Methods We assessed out-of-hospital SCD by applying the
validated computer definition and linking data with Hospital
Episode Statistics and death certificates. We developed a
separate algorithm to identify end-of-life care in noninsti-
tutionalized patients and excluded associated deaths from
the analysis to address their misclassification as SCD.
Results Of the 681,104 patients in the study cohort, 3444 were
initially classified as out-of-hospital SCD. Next, 163 deaths
were identified as expected deaths by our algorithm for end-of-
life home care. After review of patient profiles, 162 were clas-
sified as expected deaths because of evidence that the patient
received palliative or end-of-life care, but one was a false
negative. The exclusion of such cases appreciably changed the
odds ratio for current exposure to domperidone compared with
non-use of study medications from 2.09 (95 % confidence
interval [CI] 1.16–3.74) to 1.71 (95 %CI 0.92–3.18). A similar
effect on the odds ratio was observed for current exposure to
metoclopramide but not to proton pump inhibitors.
Conclusions Our algorithm to identify end-of-life care at
home in the CPRD performed well, with only one false nega-
tive. The exclusion of misclassified cases of SCD reduced the
magnitude of the odds ratios for SCD associated with dom-
peridone and metoclopramide exposure by controlling proto-
pathic bias.
Key Points
We developed an algorithm to identify end-of-life
care in noninstitutionalized patients and excluded
associated deaths from the analysis to address their
misclassification as sudden cardiac death (SCD). The
algorithm performed well, with only one false
negative.
The exclusion of misclassified cases of SCD reduced
the magnitude of the odds ratios for SCD associated
with domperidone and metoclopramide exposure by
controlling protopathic bias.
1 Introduction
The ascertainment of sudden cardiac death (SCD) in
electronic health databases is challenging. A computer
definition of SCD that was developed and validated using
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information collected in the Tennessee Medicaid program,
with an overall positive predictive value (PPV) of 86.8 %,
has been applied in several studies evaluating the risk of
SCD associated with medications [1].
We used this computer definition to identify the cases in a
recent retrospective study using data from the Clinical
Practice Research Datalink (CPRD) in theUK that examined
the relation of exposure to domperidone, a peripherally
acting dopamine 2 receptor antagonist with both gastroki-
netic and antiemetic actions, with the risk of SCD [2]. Other
retrospective epidemiologic studies have examined this
association and found an increased risk of serious ventricular
arrhythmia and SCD in patients currently exposed to dom-
peridone compared with patients not currently exposed
[3–6]. However, this was the first such study to also include
as a comparator metoclopramide, another medication with
gastrokinetic and antiemetic actions but that has not been
documented as associated with an increased risk of SCD.
Inclusion of such a comparator was important because the
indications for domperidone andmetoclopramide weremore
similar than those for domperidone and the other comparator,
proton pump inhibitors (PPIs).
Out-of-hospital SCD was ascertained by applying an
adaptation of the algorithm published by Chung et al. [1],
using information in CPRDGOLD data linked with Hospital
Episode Statistics (HES) and death certificates collected by
the Office for National Statistics (ONS). The study con-
firmed that, compared with non-use of any study drug, cur-
rent domperidone use was associated with SCD and
indicated that the increased risk was concentrated in the first
15 days of exposure in older individuals and in users of
higher daily doses. An unexpected finding was a strong
association between exposure to metoclopramide and an
increased risk of SCD.Whenwe pursued this association, we
found that some of the SCD cases exposed to metoclo-
pramide and someof those exposed to domperidone had been
under palliative care shortly before death. Because SCD is,
by definition, unexpected, these deaths were misclassified
when the electronic algorithm identified them as SCD cases.
We therefore reclassified all such SCD ‘‘cases’’ as non-cases
and appropriately revised the estimates of association.
In this short communication, we evaluate the applica-
bility of the validated computer definition of SCD [1] to
electronic medical record data recorded from general
practitioners in the UK that contribute data to the CPRD.
This information may help future CPRD researchers
improve the performance of the computer definition via
appropriate identification of palliative care, including
home-based end-of-life care in noninstitutionalized
patients, that was not identified by the adapted computer
case definition in our study. To address this misclassifica-
tion, we created a separate algorithm to identify such cases
and excluded them from the analysis.
2 Methods
The study population was derived from CPRD GOLD data
and included individuals with permanent registration status
in English practices whose data were linkable to HES and
ONS data. Subjects entered the study cohort at their first
exposure to a study drug (domperidone, any PPI medica-
tion, or metoclopramide) after at least 1 year of continuous
enrollment in the CPRD GOLD database during the period
1 January 2005 through 31 December 2011. They had to be
at least 2 years of age upon cohort entry. We excluded
subjects with a diagnosis of cancer other than non-me-
lanoma skin cancer and subjects residing in institutions.
Follow-up of subjects continued until the earliest of (1)
being transferred out of the practice, (2) last data collection
date for each subject, (3) death, (4) receiving a code for
diagnosis of cancer, (5) receiving a code for being trans-
ferred to an institutional setting, and (6) exiting the study.
All hospital episodes, each defined by admission date
and discharge date plus 30 days after the discharge date,
were identified. Person-time during these hospital episodes
was excluded to ensure that time at risk occurred outside a
hospital setting.
2.1 Ascertainment of Sudden Cardiac Death (SCD)
The study outcome was SCD, defined as an unexpected death
from circulatory arrest, usually due to a cardiac arrhythmia,
that occurredout of the hospital. The death had tobeconsistent
with a cardiac cause, meaning absence of evidence of a non-
cardiac underlying process responsible for the death. Sudden
cardiac death could present as (1) a witnessed sudden collapse
with no pulse or respiration and death occurring within 1 h
after the onset of cardiovascular symptoms or (2) an unwit-
nessed death in a person known to be alive and in stable con-
dition in the 24 h before the death was reported [1, 3, 7].
All deaths occurring during the observation period
(2005–2011) were ascertained independently of exposure
history by screening the electronic medical records for
Read codes indicating death, by identifying patients with
death recorded as the reason for transferring out of the
practice, and by linkage of the CPRD GOLD with ONS
death certificate information to obtain date and place of
death, underlying cause of death, and all other causes of
death listed on the death certificate [2]).
2.1.1 Adaptation of the Validated Computer SCD
Definition
The original computer definition for SCD included the
following components: (1) no evidence of a terminal
institutional stay, (2) underlying cause of death consistent
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with SCD based on specific cause-of-death codes that are
highly predictive of SCD, and (3) no terminal procedures
(radiology, thrombolysis, general anesthesia) inconsistent
with unresuscitated cardiac arrest [1]. In addition, we
excluded patients with evidence of a life-threatening non-
cardiac illness from the cohort.
In our study, we excluded terminal institutional stays
from the cohort. Therefore, we identified deaths with an
underlying cause of death consistent with SCD based on
the published list of International Classification of Dis-
eases and Related Health Problems, 10th revision (ICD-
10) diagnosis codes [1]. From these, we retained only
deaths that occurred within the study observation period
with a date of death outside a hospital episode.
In the original computer SCD definition, deaths from
cardiac arrests that occurred outside the hospital but were
attended in an emergency department setting were included
as cases of SCD unless terminal procedures in the emer-
gency department were inconsistent with unresuscitated
cardiac arrest [1]. In our study, it was not possible to apply
this criterion and include such subjects because informa-
tion on procedures that occurred during emergency
department visits were available only in HES data, and
HES data contained only those emergency visits that
resulted in an inpatient admission.
In addition, we excluded cases of SCD that occurred
within 30 days of an acute event: a medical encounter with
acute stroke (ischemic or hemorrhagic), myocardial
infarction, or heart failure as the principal, primary, or first-
listed diagnosis.
2.1.2 Development of Algorithm for End-of-Life
Home Care
Using National Health Service (NHS) guidelines for pal-
liative and end-of-life care [8], we identified expected
cases of death in patients with evidence of palliative or
terminal care shortly before the death by screening all
suspected cases of SCD for the following codes:
• A palliative care code within 45 days before the date of
death or
• Specific medication code(s) within 14 days before the
date of death that included (1) a prescription for any
of the following: any morphine except apomorphine,
oxycodone injections, and fentanyl patches or other
noninjectable fentanyl formulations and (2) a pre-
scription for any of the following medications:
cyclizine, haloperidol, levomepromazine, metoclo-
pramide (intravenous formulation), midazolam, gly-
copyrronium, hyoscine hydrobromide, and hyoscine
butylbromide.
The Read and product codes used are listed in the
Electronic Supplementary Material.
2.1.3 Review of Patient Profiles
Detailed chronological electronic patient profiles were
developed for all SCD cases that were reclassified by the
end-of-life home care algorithm and were reviewed by two
physicians (AA and CVL) to determine whether the algo-
rithm excluded SCD cases that were truly expected deaths.
Cases were reclassified as non-SCD cases if (1) codes were
recorded for palliative care within 45 days before the date
of death or (2) codes were recorded within 14 days before
the date of death for at least two specific medications, one
from each of the classes described previously, and were
prescribed for end-of-life care.
Final cases of SCD were cardiac deaths with an under-
lying cause-of-death diagnosis code consistent with SCD
and without an alternative noncardiac cause of death, such
as pneumonia or substance overdose, that occurred in a
noninstitutional setting. The case index date was the date of
death as verified by the death certificate information.
2.2 Analyses
We describe the number and distribution of the cases
according to the classification obtained with application of
only the adapted validated computer case definition and
with the addition of the algorithm for end-of-life home
care. We present the multivariate adjusted effect of the
study exposures to domperidone, PPIs, and metoclo-
pramide on SCD using conditional logistic regression
analysis for the two groups of cases identified. The mutu-
ally exclusive exposure categories to the study drugs were
defined as follows:
• Current use: Time from date of prescription to end of
calculated duration of exposure (duration of prescrip-
tion plus 7 days).
• Past use: The 60 days after the end of a current use time
window.
• Non-use: Study person-time outside of current use or
past use windows.
3 Results
The final study cohort comprised 681,104 subjects. Among
these, 58,647 deaths were identified in the study cohort
from the ONS linkage. Details on cohort creation are
provided in the publication of the main study [2].
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3.1 Electronically Identified SCD Cases
in the Overall Cohort
Using the adaptation of the algorithm developed and vali-
dated by Chung et al. [1], 9765 of all identified deaths had
a cardiovascular diagnosis as the underlying cause, and
3509 of these occurred outside a hospital episode during
the study follow-up. Because 65 of these had an alternative
explanation as a cause of death, a total of 3444 were ini-
tially classified as out-of-hospital SCD.
3.1.1 Application of the Algorithm for End-of-Life Home
Care to All Identified SCD Cases
In a further step, 163 deaths were identified as expected
deaths by our algorithm developed to identify palliative/
end-of-life home care. After review of the patient profiles,
162 were classified as expected deaths because of evidence
that the patient received palliative care or end-of-life
treatment. One, a case of low back pain treated with
morphine, was a false negative (1 of 163 = 0.6 %; 95 %
confidence interval [CI] 0.03–2.98; exact confidence limits
calculated with Episheet) [9].
Finally, 3282 cases met the operational study definition
of out-of-hospital SCD. Reclassification of cases based on
the application of the algorithm is shown in Table 1.
3.2 Effect of the Misclassification on Study Relative
Risk Estimates
Table 2 shows the study odds ratios estimated for current
exposure to domperidone, metoclopramide, and PPIs
before and after reclassification of cases. Of the initial 3444
SCD cases identified by applying the adapted version of the
computer definition by Chung et al. [1], 47 could not be
matched with at least one control, so the total number of
Table 1 Attrition table for
deaths
Category of death Number of
patients
Total deaths in study cohort from ONS linkage 58,647
Deaths with selected cardiovascular diagnosis as underlying cause (diagnosis code from
Chung et al. [1])
9765
Deaths occurring outside a hospital episode 5664
Deaths during study period/patient follow-up 3509
Deaths that have an alternative noncardiac cause of death 65
Total number of cases of SCD, by adapted computer definition of Chung et al. [1] 3444
Palliative/terminal care within 45 days prior to date of death 162
Total number of final cases of SCD 3282
ONS Office for National Statistics, SCD sudden cardiac death
Table 2 Risk of sudden cardiac death, according to the two sets of cases and controls, by study exposures, nested case–control analysis results of
multivariable conditional logistic regression
Exposure category (categories are mutually exclusive) SCD cases–SET 1a (N = 3397) SCD cases–SET 2b (N = 3239)
N (%) Adjusted ORc (95 % CI) N (%) Adjusted ORc (95 % CI)
Current exposure to domperidone 31 (0.9) 2.09 (1.16–3.74) 28 (0.9) 1.71 (0.92–3.18)
Current exposure to PPI 2007 (59.1) 1.32 (1.18–1.48) 1935 (59.7) 1.35 (1.21–1.51)
Current exposure to metoclopramide 48 (1.4) 4.93 (2.82–8.64) 37 (1.1) 4.31 (2.33–7.98)
Current combined exposured 120 (3.5) 3.08 (2.20–4.31) 96 (3.0) 2.68 (1.87–3.83)
Past exposure to any study drug 367 (10.8) 1.23 (1.04–1.46) 341 (10.5) 1.20 (1.01–1.43)
No exposure to any study drug 824 (24.3) Reference 802 (24.8) Reference
CI confidence interval, OR odds ratio, PPI proton pump inhibitors, SCD sudden cardiac death
a SET 1 = cases of SCD, using adapted Chung et al. [1] algorithm
b SET 2 = cases of SCD, using both the adapted Chung et al. [1] algorithm and the study palliative/terminal home care algorithm
c OR matched for age, sex, and practice, and adjusted for covariates: history of serious ventricular arrhythmia, myocardial infarction, heart
failure, valvular heart disease including valve replacement, cardiomyopathy, other arrhythmia or conduction disorder, epilepsy, depression, group
2 QTc-prolonging drugs, drugs that affect hERG, digoxin, diuretics, laxatives, beta-blockers, body mass index, alcohol use, smoking history,
number of general practitioner visits, and number of hospital admissions
d Current exposure to more than one study drug: domperidone ? PPI, domperidone ? metoclopramide, PPI ? metoclopramide, or
domperidone ? PPI ? metoclopramide
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cases in the nested case–control analysis was 3397. Our
final classification via the additional application of the
algorithm for palliative/end-of-life home care resulted in
3282 cases of SCD, 43 of which could not be matched with
at least one control, so the total number of cases in the
nested case–control analysis was 3239.
The exclusion of cases with palliative or end-of-life
home care did not modify dramatically the distribution of
cases among each exposure category. The odds ratio for
current PPI use compared with no use of any study drug
was similar for each classification process: 1.32 (95 % CI
1.18–1.48) before and 1.35 (95 % CI 1.21–1.51) after
excluding cases with end-of-life home care.
The exclusion of such cases did appreciably change the
estimate for current exposure to domperidone, which was
the estimate of primary interest in the study. Compared
with non-use of study medications, the original estimate
was 2.09 (95 % CI 1.16–3.74), and the corrected estimate
was 1.71 (95 % CI 0.92–3.18). A similar effect was
observed for current exposure to metoclopramide com-
pared with non-use of study medications; the estimate
changed from 4.93 (95 % CI 2.82–8.64) to 4.31 (95 % CI
2.33–7.98) after the exclusion of the misclassified cases.
These results were expected because domperidone and
metoclopramide can be used for palliative care in diseases
other than cancer. Nausea and vomiting are among the
commonest symptoms in patients under palliative care, and
UK guidelines indicate that side effects of opioid anal-
gesics used for palliative care are nausea and vomiting,
which are common in opioid-naı¨ve patients and can be
prevented by access to an antiemetic, e.g., metoclopramide
[8].
4 Conclusion
We have evaluated the applicability of a published vali-
dated computer definition of SCD, developed using Med-
icaid data in the USA, to a different data source (CPRD)
and healthcare system (UK). The use of detailed informa-
tion recorded by general practitioners from the UK helped
us to improve the applicability of the computer algorithm
by additional identification of expected deaths due to
home-based palliative end-of-life care. Our algorithm to
identify home-based palliative care performed well, with
only one false negative. The identification and exclusion of
these misclassified cases of SCD reduced the magnitude of
the odds ratios for SCD associated with domperidone and
metoclopramide exposure by controlling protopathic bias.
This bias may be present when estimating the risk of SCD
associated with any medications used for palliative or end-
of-life care. We would recommend using all available
relevant information to identify and exclude subjects who
receive palliative end-of-life care from database studies
that examine the association of exposure to a medication
with the risk of SCD.
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